NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-23-073 from the NIH Guide for Grants and Contracts
Notice NOT-TR-23-023 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-OD-23-020 from the NIH Guide for Grants and Contracts. The goal of this NOFO is to support doctoral candidates studying high-priority areas of child health for the completion of their doctoral dissertation research project. This NOFO seeks to advance research in child health by stimulating the use of Environmental Influences on Child Health (ECHO) Cohort data by doctoral students in relevant scientific areas. This RFA will provide students working on dissertations the opportunity to access the ECHO data within the NICHD Data and Specimen Hub (DASH) repository. ECHOs DASH dataset integrates deidentified longitudinal data from more than 41,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHOs five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health. This award will facilitate the entry of promising new investigators into the field of early environmental exposures and child health research, enhancing the pool of highly talented researchers. NIH encourages applications particularly from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).
Funding Opportunity RFA-OD-23-019 from the NIH Guide for Grants and Contracts. This NOFO seeks to advance research and training in high-priority areas of child health by stimulating the use of Environmental Influences on Child Health Outcomes (ECHO) Cohort data by postdoctoral fellows from relevant scientific communities. This RFA will provide opportunities for fellows to study child health outcomes through the analysis of ECHOs large longitudinal data sets within the NICHD Data and Specimen Hub (DASH) repository. ECHOs DASH dataset integrates deidentified longitudinal data from more than 41,000 participants across the U.S. Prenatal and child exposure data include physical, chemical, social, behavioral, and biological factors. ECHOs five primary pediatric outcome areas are pre-, peri-, and postnatal outcomes, upper and lower airway, obesity, neurodevelopment, and positive health.
Notice NOT-AG-23-032 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-071 from the NIH Guide for Grants and Contracts
Notice NOT-NR-23-011 from the NIH Guide for Grants and Contracts
Notice NOT-TR-23-024 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-090 from the NIH Guide for Grants and Contracts
Notice NOT-MD-23-017 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-23-027 from the NIH Guide for Grants and Contracts. The Ethical, Legal and Social Implications (ELSI) Research Program of the National Human Genome Research Institute (NHGRI) solicits application for the renewal of the Center for ELSI Resources and Analysis (CERA). Building on work completed during the initial funding period, CERA will: 1) provide ELSI researchers with a stable platform to share ELSI research products related to genomics; 2) curate and synthesize ELSI research; and 3) facilitate new research collaborations and uptake of ELSI research. CERA will increase the availability and visibility of ELSI products and resources and serve as a source of expertise for the larger research and policy communities.
Funding Opportunity RFA-ES-23-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support a Chemical Exposure Resource and Coordination Core (ExRC) that will provide infrastructure, management, and research support for studies of Chemicals of Concern (CoC) to the Chemical Countermeasures Research Program (CCRP). This core, established across diverse geographical regions, is intended to support multidisciplinary CCRP investigators, through development of infrastructure and exposure protocols for selected toxicants. The ExRC will provide facility access for using diverse models to characterize pathophysiological mechanisms and evaluating potential medical countermeasures through early-stage development efforts supported by the CCRP.
Notice NOT-CA-23-074 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-141 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HG-23-026 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This Informatics Tools for the Pangenome FOA will provide multiple awards to develop informatics tools that enable uptake and use of the improved pangenome reference. Emphasis will be on tools for common use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. Possible examples include selecting the best subset of linear genomes or paths along the graph for a given set of samples, visualizing complex variation, and annotating regulatory elements and disease associations.
Funding Opportunity RFA-HG-23-025 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This FOA will establish the Human Pangenome Coordinating Center (HPCC), the central component of the HGRP. The HPCC will serve as the logistic and scientific coordinating center for the HGRP and will create, improve, release, and maintain new pangenome reference versions. The overall goal of the HGRP during the renewal is to produce a human pangenome reference that optimizes both the population genetic diversity represented, along with the utility for, and adoption by, the genomics research community. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-004 are eligible to apply.
Funding Opportunity RFA-HG-23-024 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute (NHGRI) will renew the NHGRI Human Genome Reference Program (HGRP). This FOA seeks applications for the production of High Quality Human Reference Genomes (HQRG) as one of three components of the renewed HGRP. The HQRG component will lead the prioritization and selection of samples from diverse participants consented for open access data release, and, with those samples, produce 200 new, very high-quality haplotype-resolved human genome assemblies for inclusion in the human pangenome reference. The HQRG component will also include a team of ethical, legal and social issues scholars who will be embedded in the overall HGRP. This team will be integrated with the consortium to help identify and navigate topics raised by the development of a human pangenome resource, including consent, data release and sovereignty, definitions of diversity, and others that may arise over time. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-002 are eligible to apply.
Notice NOT-GM-23-046 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-195 from the NIH Guide for Grants and Contracts. The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.